Most-Upgraded StocksMost-UpgradedNASDAQ:ALNY Alnylam Pharmaceuticals (ALNY) Stock Price, News & Analysis $276.76 -2.41 (-0.86%) (As of 11:07 AM ET) Add Compare Share Share Today's Range$276.65▼$280.1750-Day Range$153.86▼$280.7652-Week Range$141.98▼$285.00Volume56,896 shsAverage Volume881,712 shsMarket Capitalization$35.01 billionP/E RatioN/ADividend YieldN/APrice Target$277.14 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Alnylam Pharmaceuticals alerts: Email Address Alnylam Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.71 Rating ScoreUpside/Downside0.7% Downside$277.14 Price TargetShort InterestHealthy3.42% of Shares Sold ShortDividend StrengthN/ASustainability-1.52Upright™ Environmental ScoreNews Sentiment0.73Based on 17 Articles This WeekInsider TradingSelling Shares$24.68 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($3.99) to ($2.38) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.60 out of 5 starsMedical Sector242nd out of 924 stocksPharmaceutical Preparations Industry98th out of 426 stocks 2.4 Analyst's Opinion Consensus RatingAlnylam Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on 17 buy ratings, 7 hold ratings, and no sell ratings.Amount of Analyst CoverageAlnylam Pharmaceuticals has been the subject of 19 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Alnylam Pharmaceuticals' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted3.42% of the outstanding shares of Alnylam Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverAlnylam Pharmaceuticals has a short interest ratio ("days to cover") of 4.Change versus previous monthShort interest in Alnylam Pharmaceuticals has recently decreased by 3.56%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldAlnylam Pharmaceuticals does not currently pay a dividend.Dividend GrowthAlnylam Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.3 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAlnylam Pharmaceuticals has received a 63.92% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Gene therapy medication", "Clinical research services", and "Preclinical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Alnylam Pharmaceuticals is -1.52. Previous Next 2.6 News and Social Media Coverage News SentimentAlnylam Pharmaceuticals has a news sentiment score of 0.73. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.44 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 17 news articles for Alnylam Pharmaceuticals this week, compared to 9 articles on an average week.Search InterestOnly 8 people have searched for ALNY on MarketBeat in the last 30 days. This is a decrease of -62% compared to the previous 30 days.MarketBeat FollowsOnly 5 people have added Alnylam Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -38% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Alnylam Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $24,683,444.00 in company stock.Percentage Held by InsidersOnly 1.50% of the stock of Alnylam Pharmaceuticals is held by insiders.Percentage Held by Institutions92.97% of the stock of Alnylam Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Alnylam Pharmaceuticals' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Alnylam Pharmaceuticals are expected to grow in the coming year, from ($3.99) to ($2.38) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Alnylam Pharmaceuticals is -104.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Alnylam Pharmaceuticals is -104.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Alnylam Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad DTIAir Force quietly working with sub $10 stock on new techThere is a little-known energy technology stock that has made an incredible breakthrough… Which could become crucial to the operations of the US Military. And right now there are plans for this stock to undertake a major test project at a US Air Force based in Alaska. Now, this incredible breakthrough is still in its earliest stages… Which means you still have a chance to get in while its trading for under $10.You need to check out the full story right here. About Alnylam Pharmaceuticals Stock (NASDAQ:ALNY)Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.Read More ALNY Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ALNY Stock News HeadlinesAugust 9, 2024 | insidertrades.comAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Director Dennis A. Ausiello Sells 20,250 SharesAugust 3, 2024 | insidertrades.comInsider Selling: Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) CEO Sells 15,148 Shares of StockAugust 22, 2024 | Stansberry Research (Ad)Millionaire Investor Warns: “Brace for Apple Collapse”Apple stock has quadrupled over the past five years. But now even Warren Buffett is pulling the plug. The Oracle of Omaha just sold HALF his stake – worth more than $75 billion in the iconic tech company.August 21 at 8:34 AM | msn.comHere’s Why Alnylam Pharmaceuticals (ALNY) Surged in Q2August 21 at 4:39 AM | americanbankingnews.comAlnylam Pharmaceuticals (NASDAQ:ALNY) Given "Buy" Rating at HC WainwrightAugust 20 at 7:45 PM | finance.yahoo.comInvesting in Alnylam Pharmaceuticals (NASDAQ:ALNY) five years ago would have delivered you a 234% gainAugust 18, 2024 | americanbankingnews.comAlnylam Pharmaceuticals (NASDAQ:ALNY) Rating Increased to Buy at The Goldman Sachs GroupAugust 17, 2024 | ca.finance.yahoo.comALNY Dec 2025 370.000 callAugust 22, 2024 | Stansberry Research (Ad)Millionaire Investor Warns: “Brace for Apple Collapse”Apple stock has quadrupled over the past five years. But now even Warren Buffett is pulling the plug. The Oracle of Omaha just sold HALF his stake – worth more than $75 billion in the iconic tech company.August 17, 2024 | msn.comGoldman Sachs Upgrades Alnylam Pharmaceuticals (ALNY)August 16, 2024 | msn.comAlnylam Pharmaceuticals Inc (ALNY)August 16, 2024 | markets.businessinsider.comBuy Rating Affirmed for Alnylam Pharmaceuticals on Strong Amvuttra Trial Results and Robust Market PotentialAugust 14, 2024 | markets.businessinsider.comBuy Rating for Alnylam Pharma Backed by Strong Investor Confidence and Promising PipelineAugust 14, 2024 | finance.yahoo.comIs There An Opportunity With Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) 47% Undervaluation?August 12, 2024 | nz.finance.yahoo.comAlnylam Pharmaceuticals, Inc. (0HD2.L)August 12, 2024 | markets.businessinsider.comDiscover New Clinical Data and Novel Developments at the 20th Annual Meeting of the Oligonucleotide Therapeutics SocietyAugust 8, 2024 | msn.comAvadel Pharmaceuticals Stock Sees RS Rating Jump to 82August 7, 2024 | investorplace.comThe 3 Best Gene Editing Stocks to Buy in August 2024See More Headlines Receive ALNY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Alnylam Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/01/2024Today8/22/2024Next Earnings (Estimated)11/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:ALNY CUSIP02043Q10 CIK1178670 Webwww.alnylam.com Phone(617) 551-8200Fax617-551-8101Employees2,100Year Founded2002Price Target and Rating Average Stock Price Target$277.14 High Stock Price Target$400.00 Low Stock Price Target$159.00 Potential Upside/Downside-0.7%Consensus RatingModerate Buy Rating Score (0-4)2.71 Research Coverage24 Analysts Profitability EPS (Most Recent Fiscal Year)($2.68) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-440,240,000.00 Net Margins-3.11% Pretax Margin-16.21% Return on EquityN/A Return on Assets-1.90% Debt Debt-to-Equity RatioN/A Current Ratio3.17 Quick Ratio3.07 Sales & Book Value Annual Sales$2.34 billion Price / Sales15.06 Cash FlowN/A Price / Cash FlowN/A Book Value($1.76) per share Price / Book-158.62Miscellaneous Outstanding Shares126,492,000Free Float124,595,000Market Cap$35.31 billion OptionableOptionable Beta0.37 Social Links 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesDr. Yvonne L. Greenstreet M.B.A. (Age 61)MBChB, CEO & Director Comp: $2.15MMr. Jeffrey V. Poulton M.B.A. (Age 56)CFO & Executive VP Comp: $1.05MDr. Akshay K. Vaishnaw M.D. (Age 61)Ph.D., Chief Innovation Officer & Member of the Scientific Advisory Board Comp: $1.12MDr. Pushkal P. Garg M.D. (Age 56)Chief Medical Officer and Executive VP of Development & Medical Affairs Comp: $1.06MMr. Tolga Tanguler M.B.A. (Age 51)Executive VP & Chief Commercial Officer Comp: $971.3kMr. Timothy J. MainesChief Technical Operations & Quality OfficerDr. Kevin Joseph Fitzgerald Ph.D. (Age 55)Senior VP, Head of Research & Chief Scientific Officer Ms. Christine Regan Lindenboom (Age 43)Senior VP of Investor Relations & Corporate Communications Mr. Piyush Sharma J.D.Chief Ethics & Compliance OfficerMr. Evan Lippman M.B.A.Chief Corporate Development & Strategy OfficerMore ExecutivesKey CompetitorsHorizon Therapeutics PublicNASDAQ:HZNPBeiGeneNASDAQ:BGNERoyalty PharmaNASDAQ:RPRXSarepta TherapeuticsNASDAQ:SRPTMyoKardiaNASDAQ:MYOKView All CompetitorsInsiders & InstitutionsTruist Financial CorpSold 623 shares on 8/21/2024Ownership: 0.001%Regal Investment Advisors LLCBought 132 shares on 8/16/2024Ownership: 0.003%Algert Global LLCBought 1,960 shares on 8/16/2024Ownership: 0.002%Northwestern Mutual Wealth Management Co.Bought 250 shares on 8/16/2024Ownership: 0.000%Quarry LPSold 776 shares on 8/16/2024Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions ALNY Stock Analysis - Frequently Asked Questions How have ALNY shares performed this year? Alnylam Pharmaceuticals' stock was trading at $191.41 at the beginning of the year. Since then, ALNY stock has increased by 45.8% and is now trading at $279.17. View the best growth stocks for 2024 here. How were Alnylam Pharmaceuticals' earnings last quarter? Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) issued its earnings results on Thursday, August, 1st. The biopharmaceutical company reported ($0.13) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.74) by $0.61. The company's quarterly revenue was up 107.0% on a year-over-year basis. What is John M. Maraganore's approval rating as Alnylam Pharmaceuticals' CEO? 65 employees have rated Alnylam Pharmaceuticals Chief Executive Officer John M. Maraganore on Glassdoor.com. John M. Maraganore has an approval rating of 99% among the company's employees. This puts John M. Maraganore in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. Who are Alnylam Pharmaceuticals' major shareholders? Alnylam Pharmaceuticals' top institutional shareholders include Baillie Gifford & Co. (4.77%), American Century Companies Inc. (1.07%), TD Asset Management Inc (0.39%) and Susquehanna International Group LLP. Insiders that own company stock include Yvonne Greenstreet, Jeffrey V Poulton, Akshay Vaishnaw, Michael W Bonney, Pushkal Garg, Kevin Joseph Fitzgerald, Amy W Schulman, Tolga Tanguler, Steven M Paul, Dennis A Ausiello, David E I Pyott, Indrani Lall Franchini and John Maraganore. View institutional ownership trends. How do I buy shares of Alnylam Pharmaceuticals? Shares of ALNY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Alnylam Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Alnylam Pharmaceuticals investors own include Alibaba Group (BABA), NVIDIA (NVDA), XOMA (XOMA), Ionis Pharmaceuticals (IONS), Gilead Sciences (GILD), NXP Semiconductors (NXPI) and Mylan (MYL). This page (NASDAQ:ALNY) was last updated on 8/22/2024 by MarketBeat.com Staff From Our PartnersWhat Is the $7,882 Stimulus Payment 2024?Biden’s government just announced a new government "stimulus program"... And it could hand you a payment fo...Angel Publishing | SponsoredAir Force quietly working with sub $10 stock on new techThere is a little-known energy technology stock that has made an incredible breakthrough… Which could becom...DTI | SponsoredMillionaire Investor Warns: “Brace for Apple Collapse”Apple stock has quadrupled over the past five years. But now even Warren Buffett is pulling the plug. The O...Stansberry Research | SponsoredTrump is sounding the alarmEurope is one of the latest to release a central bank digital currency and along with it, new cash rules. Chri...Preserve Gold | SponsoredUS developing “superweapon” to defeat China and Russia?Our new superweapon is a gift to every patriot. I predict the devastating new tech behind this weapon will cre...Paradigm Press | SponsoredGrab this ETF paying a huge 22% dividendImagine a world where you don't have to stress about inflation eroding your savings... Where your paycheck ...Investors Alley | SponsoredAmazon coin set to soar 25X – starting August 19thChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredAlex's "Next Magnificent Seven" StocksToday Alex Green is releasing his new breakdown of AI's "Next Magnificent Seven." So please make some time ...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alnylam Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alnylam Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ALNY Stock Alerts